Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have received a consensus rating of “Moderate Buy” from the seven ratings firms that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $18.00.

Several research firms have issued reports on VYGR. Oppenheimer restated an “outperform” rating and set a $18.00 price objective on shares of Voyager Therapeutics in a report on Wednesday, May 15th. StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, May 13th. Wedbush dropped their price objective on Voyager Therapeutics from $10.00 to $8.00 and set a “neutral” rating on the stock in a report on Tuesday, May 14th. Citigroup started coverage on Voyager Therapeutics in a report on Thursday, March 7th. They issued a “buy” rating and a $16.00 price target for the company. Finally, Guggenheim started coverage on Voyager Therapeutics in a report on Tuesday, March 26th. They issued a “buy” rating and a $22.00 price target for the company.

Institutional Investors Weigh In On Voyager Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Armistice Capital LLC boosted its position in Voyager Therapeutics by 1.4% during the 4th quarter. Armistice Capital LLC now owns 4,236,000 shares of the company’s stock valued at $35,752,000 after purchasing an additional 58,000 shares during the period. Vanguard Group Inc. boosted its position in Voyager Therapeutics by 27.8% during the 1st quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock valued at $30,087,000 after purchasing an additional 702,030 shares during the period. Farallon Capital Management LLC boosted its position in Voyager Therapeutics by 77.4% during the 1st quarter. Farallon Capital Management LLC now owns 2,292,000 shares of the company’s stock valued at $21,339,000 after purchasing an additional 1,000,000 shares during the period. Price T Rowe Associates Inc. MD boosted its position in Voyager Therapeutics by 3.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,041,930 shares of the company’s stock valued at $9,702,000 after purchasing an additional 37,144 shares during the period. Finally, Acadian Asset Management LLC boosted its position in Voyager Therapeutics by 10.1% during the 1st quarter. Acadian Asset Management LLC now owns 459,850 shares of the company’s stock valued at $4,280,000 after purchasing an additional 42,029 shares during the period. 48.03% of the stock is currently owned by institutional investors.

Voyager Therapeutics Stock Performance

Shares of NASDAQ:VYGR opened at $7.86 on Tuesday. Voyager Therapeutics has a one year low of $6.06 and a one year high of $11.72. The business’s 50-day simple moving average is $8.27 and its 200 day simple moving average is $8.40. The company has a market cap of $427.51 million, a P/E ratio of -157.17 and a beta of 0.96.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.24. Voyager Therapeutics had a negative return on equity of 1.28% and a negative net margin of 2.56%. The company had revenue of $19.52 million for the quarter, compared to the consensus estimate of $10.33 million. Analysts predict that Voyager Therapeutics will post -1.39 earnings per share for the current year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.